Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • BI 655066 - Psoriasis
    Clinical Study Number 1311.2
    Study Indication Psoriasis
    Product BI 655066
    Generic Name BI 655066
    Lab Code
    Clinical Phase II
    Study Title

    A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-controlled (ustekinumab), double-blind within dose groups of BI 655066)

    Study Document
    Trial synopsis 1311.2_DR english
  • BIRT 2584 - Psoriasis
    Clinical Study Number 1206.5
    Study Indication Psoriasis
    Product BIRT 2584
    Generic Name BIRT 2584
    Lab Code
    Clinical Phase IIa/b
    Study Title

    A 12 week double-blind, randomised, placebo-controlled, modified dose escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily inpatients with moderate to severe psoriasis with a 12 week treatment extensionfor PASI 50 responders.

    Study Document
    Trial synopsis 1206.5 english
  • Doramapimod - Psoriasis
    Clinical Study Number 1175.10
    Study Indication Psoriasis
    Product Doramapimod
    Generic Name Doramapimod
    Lab Code
    Clinical Phase IIa
    Study Title

    Phase ll, Randomized, Double-blind, Placebo Controlled, Multicenter, Four Week Trial of BIRB 796 BS 5, 10, 20 and 30 mg Oral Tablets Versus Placebo Administered BID in Patients with Moderate to Severe Plaque-Type Psoriasis

    Study Document
    Trial synopsis 1175.10 english
  • CYLTEZO ® - Psoriasis
    Clinical Study Number 1297.12
    Study Indication Psoriasis
    Product CYLTEZO ®
    Generic Name Adalimumab-adbm
    Lab Code BI 695501
    Clinical Phase III
    Study Title

    Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

    Study Document
    Trial synopsis 1297.12 english
    Lay summary 1297.12 english
    Lay summary 1297.12 czech
    Lay summary 1297.12 estonian
    Lay summary 1297.12 german
    Lay summary 1297.12 polish
    Lay summary 1297.12 slovak